• Stockholm3 study is named the best scientific publication by the European Association of Urology

  • Stockholm3 – the future of prostate cancer diagnostics

  • “Stockholm3 combines accurate diagnosis of prostate cancer with improved health economics”

    Read more in Läkartidningen

Want to take Stockholm3?

Prostate cancer is the second most common cancer in the world, 1.4 million men are diagnosed yearly. Early detection is the key to successful treatment. Currently, a number of healthcare providers offer Stockholm3.

  • 75000

    Participants in clinical studies

  • 100 %

    More cases of aggressive cancers found

  • 50 %

    Fewer unnecessary biopsies

  • 17-28 %

    Reduced healthcare costs


A3P Biomedical’s lead product is Stockholm3, a blood test that combines protein markers, genetic markers and clinical data with a proprietary algorithm in order to detect aggressive prostate cancer at an early stage.